Pure Global
NCT00638612

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer
Candel Therapeutics, Inc.·Phase 1·ClinicalTrials.gov·biologicalCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pancreatic Adenocarcinoma,Pancreatic Cancer
Drug/Device/Intervention
AdV-tk
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Candel Therapeutics, Inc.
Location
Duarte,La Jolla,Columbus, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Aug 01, 2008
End date
Jun 01, 2015
Enrollment
27 participants
Primary outcome

Incidence of treatment emergent adverse events

Summary

The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene
 Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral
 vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk),
 followed by an antiherpetic prodrug, valacyclovir.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Other parts of pancreasMalignant neoplasm: Tail of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00638612
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00638612 through Pure Global AI's free database. This Phase 1 trial is sponsored by Candel Therapeutics, Inc. and is currently Completed. The study focuses on Pancreatic Adenocarcinoma,Pancreatic Cancer. Target enrollment is 27 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.